Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Total Non-Current Liabilities data on record, last reported at $25.3 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 15.69% year-over-year to $25.3 million; the TTM value through Dec 2025 reached $25.3 million, down 15.69%, while the annual FY2025 figure was $25.3 million, 15.69% down from the prior year.
  • Total Non-Current Liabilities reached $25.3 million in Q4 2025 per LCTX's latest filing, up from $24.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $59.3 million in Q1 2022 and bottomed at $10.9 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $36.5 million, with a median of $39.0 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 442.02% in 2022, then decreased 25.71% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $11.6 million in 2021, then skyrocketed by 346.53% to $51.7 million in 2022, then decreased by 24.61% to $39.0 million in 2023, then decreased by 22.95% to $30.0 million in 2024, then dropped by 15.69% to $25.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $25.3 million in Q4 2025, $24.9 million in Q2 2025, and $30.0 million in Q4 2024.